Red Light Holland has expanded its clinical research capabilities following its acquisition of Filament Health, supporting shipments of the botanical psilocybin drug candidate PEX010 to several Canadian institutions. These shipments back ongoing and new clinical trials exploring psilocybin's effects on psychological distress in palliative care, treatment-resistant bipolar depression, and the mechanisms of psychedelic experiences in healthy adults. The company aims to advance psychedelic medicine research and maintain its role as a key supplier of pharmaceutical-grade natural psilocybin. Future steps include supporting multi-site Phase 3 trials and further mechanistic studies to broaden understanding and therapeutic applications of psilocybin.
